Hong Kong PR

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - August 21, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that as a result of strong investor demand, the Company has increased the size of its previously announced "bought deal" public offering (the "Underwritten Offering") from gross proceeds of approximately C$5,000,000 to gross proceeds of approximately C$6,000,000. Pursuant to the upsized Underwritten Offering, Red Cloud Securities Inc. ("Red Cloud"), as sole underwriter and bookrunner, has agreed to purchase for resale 6,666,667 units of the Company (each, a "Unit") at a price of C$0.90 per Unit (the "Offering Price").Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to purchase one common share of the Company (each, a "Warrant Share") at a price of C$1.35 at any time on or before that date which is 36 months after the Closing Date (as herein defined).The Company has granted to the Underwriter an option (the "Over-Allotment Option", and together with the Underwritten Offering, the "Offering"), exercisable, in whole or in part, at any time for a period of up to 30 days after and including the Closing Date, to purchase for resale the number of additional Units equal to up to 15% of the number of Units sold pursuant to the Underwritten Offering at the Offering Price to cover over allotments, if any, and for market stabilization purposes.The net proceeds from the Offering will be used by the Company to fund ongoing operations including, but not limited to, commercial development, product development and working capital. In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement") to the Company's final short form base shelf prospectus dated March 7, 2025 (the "Shelf Prospectus"), with the securities regulatory authorities in each of the provinces and territories of Canada, except Quebec. The Units may also be sold in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and in such other jurisdictions outside of Canada and the United States, in each case in accordance with all applicable laws provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction, and provided the issuance of the Units (including the underlying securities) is permitted under laws applicable to the Company (including the Australian Corporations Act 2001 (Cth).Copies of the Shelf Prospectus and the Supplement to be filed in connection with the Offering, can be found on SEDAR+ at www.sedarplus.ca. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering. Prospective investors should read the Supplement, the Shelf Prospectus and the other documents the Company has filed on SEDAR+ at www.sedarplus.ca before making an investment decision.The Offering is expected to close on or about September 3, 2025 (the "Closing Date"), or on such date as agreed upon between the Company and Red Cloud. The closing of the Offering is subject to the Company receiving all necessary regulatory approvals, including the approval of the TSX Venture Exchange to list, on the Closing Date, the common shares of the Company issuable from the sale of Units as well as upon the exercise of the Warrants.This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.About GMGGMG is an Australian-based clean-technology company, which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in-house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low-cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy saving coating), which is now being marketed into other applications, including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium ion batteries.GMG's 4 critical business objectives are:Produce Graphene and Improve/Scale Cell Production ProcessesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the expected size and terms of the Offering, the anticipated timing of closing the Offering, the ability of the Company to satisfy all conditions to closing the Offering, and the expected use of proceeds from the Offering.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, expectations and assumptions concerning the business objectives of the Company; the Company's ability to carry out current planned capital projects, research and development, manufacturing, production, sales and marketing programs for its graphene and graphene-enhanced products and solutions; that the Company will receive the necessary regulatory approvals for the Offering; use the proceeds from the Offering as anticipated; the Company's performance and general business and economic conditions.Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: the risk that the Company is not able to use the proceeds from the Offering as anticipated by management; the risk that the Company does not receive the requisite regulatory approvals for the Offering; overall economic conditions; technical de-risking and market acceptance for the Company's products and solutions; the introduction of competing technologies or products; stock market volatility; environmental and regulatory requirements; competitive pressures; change in market conditions and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied in these forward-looking statements; the volatility of global capital markets; political instability; the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel; unexpected development and production challenges; unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/263313 Copyright 2025 ACN Newswire via SeaPRwire.com.

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - August 21, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that as a result of strong investor demand, the Company has increased the size of its previously announced "bought deal" public offering (the "Underwritten Offering") from gross proceeds of approximately C$5,000,000 to gross proceeds of approximately C$6,000,000. Pursuant to the upsized Underwritten Offering, Red Cloud Securities Inc. ("Red Cloud"), as sole underwriter and bookrunner, has agreed to purchase for resale 6,666,667 units of the Company (each, a "Unit") at a price of C$0.90 per Unit (the "Offering Price").Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to purchase one common share of the Company (each, a "Warrant Share") at a price of C$1.35 at any time on or before that date which is 36 months after the Closing Date (as herein defined).The Company has granted to the Underwriter an option (the "Over-Allotment Option", and together with the Underwritten Offering, the "Offering"), exercisable, in whole or in part, at any time for a period of up to 30 days after and including the Closing Date, to purchase for resale the number of additional Units equal to up to 15% of the number of Units sold pursuant to the Underwritten Offering at the Offering Price to cover over allotments, if any, and for market stabilization purposes.The net proceeds from the Offering will be used by the Company to fund ongoing operations including, but not limited to, commercial development, product development and working capital. In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement") to the Company's final short form base shelf prospectus dated March 7, 2025 (the "Shelf Prospectus"), with the securities regulatory authorities in each of the provinces and territories of Canada, except Quebec. The Units may also be sold in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and in such other jurisdictions outside of Canada and the United States, in each case in accordance with all applicable laws provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction, and provided the issuance of the Units (including the underlying securities) is permitted under laws applicable to the Company (including the Australian Corporations Act 2001 (Cth).Copies of the Shelf Prospectus and the Supplement to be filed in connection with the Offering, can be found on SEDAR+ at www.sedarplus.ca. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering. Prospective investors should read the Supplement, the Shelf Prospectus and the other documents the Company has filed on SEDAR+ at www.sedarplus.ca before making an investment decision.The Offering is expected to close on or about September 3, 2025 (the "Closing Date"), or on such date as agreed upon between the Company and Red Cloud. The closing of the Offering is subject to the Company receiving all necessary regulatory approvals, including the approval of the TSX Venture Exchange to list, on the Closing Date, the common shares of the Company issuable from the sale of Units as well as upon the exercise of the Warrants.This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.About GMGGMG is an Australian-based clean-technology company, which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in-house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low-cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy saving coating), which is now being marketed into other applications, including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium ion batteries.GMG's 4 critical business objectives are:Produce Graphene and Improve/Scale Cell Production ProcessesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the expected size and terms of the Offering, the anticipated timing of closing the Offering, the ability of the Company to satisfy all conditions to closing the Offering, and the expected use of proceeds from the Offering.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, expectations and assumptions concerning the business objectives of the Company; the Company's ability to carry out current planned capital projects, research and development, manufacturing, production, sales and marketing programs for its graphene and graphene-enhanced products and solutions; that the Company will receive the necessary regulatory approvals for the Offering; use the proceeds from the Offering as anticipated; the Company's performance and general business and economic conditions.Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: the risk that the Company is not able to use the proceeds from the Offering as anticipated by management; the risk that the Company does not receive the requisite regulatory approvals for the Offering; overall economic conditions; technical de-risking and market acceptance for the Company's products and solutions; the introduction of competing technologies or products; stock market volatility; environmental and regulatory requirements; competitive pressures; change in market conditions and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied in these forward-looking statements; the volatility of global capital markets; political instability; the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel; unexpected development and production challenges; unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/263313 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年8月22日 - (亞太商訊 via SeaPRwire.com) - 光大永年有限公司，為中國光大集團旗下物業租賃、及物業管理及銷售持作出售物業公司（「光大永年」或「集團」，香港聯交所股份代號：03699.HK）今天公佈截至2025年6月30日止（「報告期內」）之中期業績。報告期內，集團的收益約為人民幣24.5百萬元（2024年：人民幣23.9百萬元），較去年同期增加約人民幣0.6百萬元，主要由於租賃收入增加所致。本公司權益股東應佔溢利約為人民幣10.1百萬元（2024年：人民幣11.4百萬元），較去年同期減少約人民幣1.3百萬元，乃主要由於中國所得稅及遞延稅項增加所致。集團錄得毛利約人民幣18.1百萬元（2024年：人民幣17.5百萬元），較去年同期增加約人民幣0.6百萬元。每股基本盈利約為人民幣2.30分（2024年：人民幣2.59分）。考慮到目前經營環境仍是面對比較大挑戰的情況下，董事會宣佈派發截至2025年6月30日止六個月之本公司中期股息每股普通股人民幣0.73分（相當於0.80港仙）（2024年：人民幣0.78分（相當於0.85港仙）），以答謝股東一直以來的支持。2025年，全球經濟環境依然充滿不確定性，地緣政治風險、通脹壓力及全球主要經濟體貨幣政策調整等因素持續影響市場信心和資本流動。儘管如此，中國經濟保持總體穩定，消費市場逐步回暖，產業結構持續優化升級，為物業管理及租賃行業提供了穩健的發展基礎。截至2025年6月底，本集團的租金收入約為人民幣17.0百萬元（2024年： 人民幣16.3百萬元），較去年同期增加約人民幣0.7百萬元，旗下物業出租率維持在約81%（2024年：77%），整體租賃市場表現穩健，但新簽訂租金水準較此前有所下降。面對租金下調壓力，本集團將通過在新租約中增加附加服務，提升綜合收益能力，緩解租金下降對整體收入的影響。此舉不僅豐富了服務內容，也有助於增強客戶粘性和滿意度，進一步鞏固本集團的市場競爭力。物業管理服務的收益約為人民幣7.5百萬元（2024年：人民幣7.6百萬元），較去年同期下降約人民幣0.1百萬元。在物業組合策略方面，本集團積極推動租戶多元化，分散行業風險，適應各行業興衰加速的市場環境。本集團現有物業主要集中於四川成都和雲南昆明兩大核心城市，涵蓋光大金融中心、光大國際大廈及明昌大廈三棟商業樓宇，總建築面積約89,507平方米。得益於優越的地理位置和良好的物業品質，吸引了大量國有企業及大型機構入駐，租賃基礎穩固。未來，本集團將推動業務多元化發展，提升整體抗風險能力。海外投資方面，本集團正評估國際市場的投資機會，體現出對海外市場的審慎樂觀態度。儘管當前全球經濟波動較大，本集團將堅持穩健原則，靈活把握投資視窗，確保資本運作的安全性和收益性。於2025年6月30日，本集團持有現金及銀行結餘以及銀行存款約為人民幣236.2百萬元（2024年12月31日：人民幣231.5百萬元）。資本負債比率（按本集團總負債除以總資產計量）為18.6%（2024年12月31日：18.0%）。本集團的流動資金狀況良好。展望2025年下半年，儘管上半年租約表現良好，但暫無新增物業管理項目。疫情期間延遲的收購及投資計劃，隨著國內經濟活躍和利率下調，市場投資意願明顯增強，本集團正積極尋找合適的投資視窗。本集團將繼續深化數位化轉型，積極運用科技，推動智慧物業建設，提升運營效率和客戶體驗。通過技術賦能，優化人力資源配置和服務流程，增強物業管理的智慧化和精細化水準，提升整體服務品質和客戶滿意度。此外，本集團將充分發揮與母公司中國光大集團的協同效應，借助“光大”品牌的知名度和資源優勢，積極拓展多元化增值服務，豐富收入結構，提升品牌影響力。面對行業轉型升級，本集團堅持穩健經營，注重風險管理和內部控制，靈活應對宏觀經濟及政策變化，持續優化資產組合，增強抗風險能力。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月22日 - (亞太商訊 via SeaPRwire.com) - 中聯發展控股集團有限公司（下稱「本公司」；聯交所編號：0264）欣然宣布，已簽訂最終協議收購香港金融科技創新企業 — NVTHK有限公司（「NVT」）20%股權。NVT為現實資產（「RWA」）代幣化市場的先行者。通過本次戰略性收購，公司已站在一個有望重塑全球資本市場，並於未來數年實現高速增長的行業前沿。NVT — 開創性市場先行者NVT是香港領先的RWA代幣化基礎設施提供商，通過其強大的OTC平台，構建了行業首個可支持頂級金融機構一級發行和受監管代幣化資產鏈上二級交易的完整生態系統。其高度整合的封閉式平台，連接資產發行人、投資者及流動性提供者，為金融業帶來前所未有的效率及流動性。NVT擁有享譽盛名的機構級客戶陣容，涵蓋頂尖金融機構、資產管理人及Web3創新企業，包括信達國際資管、廣發證券、金洲資產管理、Animoca Brands及HashKey Group。現時平台支援多類型金融產品的代幣化發行，如貨幣市場基金、結構性產品、債券及私募股權基金，展現其廣泛應用及市場認可度。此次收購對中聯發展控股的戰略意義根據波士頓諮詢集團（BCG）於2025年4月發布的報告，全球RWA代幣化市場預計將由2025年的0.6萬億美元在中位情景下增長至2033年的18.9萬億美元，年均復合增長率達53%。該行業的快速擴張反映了機構及零售投資者對高收益、透明且易於直接投資的資產類別的需求日益增加。透過收購NVT 20%股權，本公司將獲得：- 經驗豐富且全面合規的一站式機構級代幣化平台；- 獨家接入香港首個可在鏈上OTC市場進行二級交易的RWA生態系統；- 已建立的全球分銷網絡 — 迅速連接流動性提供者、資產發行人及投資者；- 與行業領袖夥伴攜手進一步建立市場公信力及拓展市場觸及範圍。本次收購大幅加速公司進軍高速增長的RWA市場，無需承擔從零自建平台所帶來的延誤、風險與資本開支。該收購亦符合本公司致力於探索創新與新業務機會，以實現收入多元化的承諾。戰略合作領域在此次投資完成後，公司與NVT將於兩大戰略範疇展開合作：皮革生產及供應鏈RWA代幣化依託NVT平台，本公司將率先於全球推動皮革行業實體及無形資產（包括現金流、應收帳款、存貨及知識產權等）的代幣化，實現營運資金釋放、開拓新投資渠道、自動化結算並拓展全球流動性。拓展新的RWA垂直領域雙方將共同開發並規模化推進其他行業的RWA解決方案，結合本公司產業專長與NVT經驗驗證的基礎設施，把握多元資產類別中的潛在機遇。中聯發展控股集團有限公司行政總裁趙靖飛表示：「本次投資NVT代表著公司跨越性發展的重要一步。NVT作為行業先行者及領導者，結合獨有鏈上一级及二級交易能力及卓越客戶基礎，令我們可深度參與萬億級增長機遇，加速核心業務數碼化並創造長遠股東價值。」NVT創辦人兼行政總裁趙建公表示：「我們的使命是運用區塊鏈技術重新定義資本市場，特別聚焦於亞洲金融中心 — 香港。通過與中聯發展的合作，我們將來自實體產業的優質資產引入並無縫對接至資本市場。此次合作不僅進一步強化了我們的平台實力，也為我們的合作夥伴生態系統創造了可觀的價值增長機遇，同時明確聚焦於為股東實現長期回報最大化。我們所構建的僅僅是一個開始 — 在未來，全新的商業模式、創新的資產類別以及可擴展的增長潛力將展現出無限可能。」關於NVTNVTHK有限公司（「NVT」）為總部位於香港的金融科技創新企業，專注現實資產（RWA）代幣化基礎設施、虛擬資產經紀系統及穩定幣技術方案。NVT 為香港首家通過 OTC 平台實現受監管代幣化資產鏈上交易的企業，為發行人、投資者及中介機構提供企業級技術解決方案。關於中聯發展控股集團有限公司中聯發展控股集團有限公司（「CIDC」）於開曼群島註冊成立，並於香港聯合交易所主板上市（股份代號：0264）。作為一家成熟的投資控股公司，CIDC 在高品質皮革製品的製造與分銷方面建立了堅實基礎。CIDC 積極推動創新與轉型戰略，尋求突破傳統核心業務的更多機遇。公司始終致力於尋找新業務與價值創造的契機，並適時擴展經營範疇與投資版圖。傳媒垂詢：NVTHK有限公司梁海燕   電話:2522 3869 電郵: Olivia.leung@newvisiongp.com網址: www.nvt.cim.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

2025 Interim Results Highlights- Total revenue increased by 9.40% YoY to approximately NTD585.31 million- Gross profit increased by 28.98% YoY to approximately NTD201.97 million- Overall gross profit margin rose by 5.24 percentage points to approximately 34.51%- Total comprehensive income attributable to owners of the Company for the period increased significantly by118.02% YoY to approximately NTD68.24 million- Revenue from turnkey solutions reached approximately NTD113.69 million- Basic earnings per share increased by 25.84% YoY to approximately NTD4.87 centsHONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Genes Tech Group Holdings Co. Ltd (“Genes Tech Group” or “The Group”, Stock Code: 8257.HK) announces its interim results for the six months ended 30 June, 2025 (“During the period”). During the period, the Group’s performance demonstrated steady growth. The total revenue of the Group reached approximately NTD585.31 million, representing a year-on- year (“YoY”) increase of 9.40%. Total comprehensive income attributable to owners of the Company for the period amounted to approximately NTD68.24 million, representing a significant YoY increase of 118.02%. Basic earnings per share were approximately NTD4.87 cents, representing a YoY increase of 25.84%.During the period, revenue from turnkey solutions amounted to approximately NTD113.69 million, accounting for approximately 19.42% of the Group’s total revenue. The revenue from trading of parts and used SME amounted to approximately NTD471.62 million, accounting for approximately 80.58% of the Group’s total revenue. The Group adheres to its core strategy of prudence and stability, striving to strengthen the stability and continuity of cooperation with existing international clients while actively expanding new clientele to diversify risks. During the period, the Group’s revenue from operations in the United States increased significantly by 78.54% from last year, accounting for approximately 38.68% of the total revenue of the Group, while revenue from operations in Taiwan increased by 48.97% from last year, accounting for approximately 49.69% of the total revenue the Group.In the first half of 2025, the global semiconductor market continued its growth momentum. Driven by new technologies such as AI, the penetration rates of new technologies and products in areas such as automotive electronics, new energy, the Internet of Things, big data and artificial intelligence continued to rise. Furthermore, the deepening development of cutting-edge technologies such as “AI+” and “5G+”, along with the rapid growth in demand for AI computing power, have become key drivers of semiconductor demand, creating a favorable development environment for semiconductor companies. According to the latest report from the Semiconductor Industry Association (SIA), global semiconductor sales reached USD59 billion in May 2025, up 19.8% from USD49.2 billion in May 2024, marking 19 consecutive months of year-on-year growth and a 3.5% increase from the previous month. The growth in the global chip market was primarily driven by strong demand from the Americas and Asia- Pacific regions.Mr. Yang Ming-Hsiang, Chairman and Chief Executive Officer concluded: “Driven by the strong momentum of AI technology, the semiconductor industry is entering a period of rapid growth in economic profits. However, amidst the current volatile international landscape, the semiconductor industry faces challenges in supply chain stability. The Group will assess the situation, pursue progress while maintaining stability, and continuously enhance its core value and competitiveness to create sustainable long-term investment returns for shareholders.”About Genes Tech Group Holdings Co. Ltd (Stock Code: 8257.HK)Genes Tech Group Holdings Co. Ltd is a turnkey solution provider and exporter of parts and used SME in Taiwan. Since the commencement of its business in 2009, the Group mainly engaged in providing turnkey solution for parts and used SME for its customers and modifying and/or upgrading the semiconductor equipment of its production systems according to customers needs. In addition, the Group is also engaged in the trading of SEM and parts. The SME and parts supplied by the Group included furnaces, clean tracks and other related items, which were used at the front-end of the semiconductor manufacturing process, wafer fabrication such as deposition, photoresist coating and development, and these were extensively applied in mobile phones, game consoles, DVD players, automotive sensors and other digital electronic products.The press release is distributed by Vitalink Consultants Limited on behalf of Genes Tech Group Holdings Co. Ltd. For enquiry, please contact:Ms. Natural Lau  Tel: (852) 2529 7999  Email: Natural.lau@vitalink.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025. During the reporting period, the Company's business showed strong growth momentum, achieving profitability for the first time. Core product sales and international licensing business progressed in tandem, with multiple ADC pipeline products entering key clinical stages and global commercialization efforts accelerating.Lepu Biopharma is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. Lepu Biopharma is dedicated to developing innovative ADCs through our comprehensive and advanced ADC technology development platform and we aim to develop optimal and innovative drugs to better serve the unmet medical needs of cancer patients. The Company is committed to continuously developing a market-differentiating pipeline by fully integrating independent innovation capabilities and strategic collaborations. The Company has established and is progressively expanding our internal manufacturing capabilities, driven by the business needs stemming from the upcoming commercialization of our ADC candidates.Currently, Lepu Biopharma has strategically designed our pipeline with a range of oncology products. For clinical-stage candidates, the Company has one clinical/commercialization-stage drug candidate; nine clinical-stage drug candidates, including one co-developed through a joint venture; and three clinical-stage combination therapies of our candidates. One of our drug candidates has obtained marketing approval with respect to two of its targeted indications, with clinical trials for other indications ongoing. Among the nine clinical-stage drug candidates, seven are targeted therapeutics and two are immunotherapeutics, which are an oncolytic virus drug and T cell agonistic antibody.As of the end of the reporting period, Lepu Biopharma has achieved significant milestones in the monetisation of our R&D capabilities through commercialization and BD activities: PUYOUHENG (Pucotenlimab Injection) has completed the full commercialization process and is currently under a rapid sales growth, and four other products, CMG901, MRG007 and two pre-clinical TCE assets have also been licensed out through our BD activities. Notably, CMG901’s global rights have been licensed to AstraZeneca, and MRG007’s rights for regions outside Greater China have been licensed to ArriVent. Two pre-clinical TCE assets have entered into a collaboration with Excalipoint.Revenue scale achieved a 3.5-fold leapfrog growth, with comprehensive improvement in financial indicatorsIn the first half of 2025, the Company made significant progress in advancing its product pipeline and business operations, recording a total revenue of approximately RMB466 million, which was an increase of 350% of the same period in 2024 at RMB133 million. For licensing activities, the Company has recognized approximately RMB309 million in revenue primarily from the out-licensing of MRG007. The Company recorded a revenue of approximately RMB151 million for the sales of PUYOUHENG (Pucotenlimab Injection), marking a significant increase of 58.8% from the sales recorded in the same period in 2024. In addition, the Group recognized approximately RMB6.3 million in revenue for the provision of CDMO services.During the reporting period, the Company achieved profitability for the first time, with a profit of approximately RMB 29.3 million, marking a turnaround from a loss in the same period of 2024. Net cash generated from operating activities was approximately RMB 46.7 million, and cash and cash equivalents increased to approximately RMB 473 million, representing a positive net operating cash flow compared to the same period in 2024. Research and development expenses amounted to approximately RMB 202 million, representing a decrease of 6.6% compared to the same period in 2024. While ensuring the advancement of core pipelines, cost control measures have shown tangible results.The Company actively develops cooperative relationships with various business channel partners. As of June 30, 2025, the Company completed the tendering process on the procurement platform in 28 provinces of the PRC. We have covered approximately 118 cities in the PRC through various sales channels, and we will further expand our sales network.ADC pipeline enters the critical phase with multiple products, potential for combination therapy highlighted, and fruitful international licensing resultsIn the first half of 2025, the Company remained focused on the research and development of its drug candidates, while continuously assessing market demand and competitive landscape relating to the range of oncology therapeutics and the broad spectrum of indications covered by its drug candidates, in order to maximize the competitiveness of its products pipeline. In particular, MRG003 for NPC nears approval and other key drug candidates advance to pivotal clinical stage.MRG003（EGFR-ADCNPC: MRG003 is under NDA review for the treatment of R/M NPC and has also been granted priority review by the CDE of NMPA. The authority is currently proceeding with the clinical and pharmaceutical evaluation of MRG003. The encouraging data of the pivotal Phase IIb clinical study for the treatment of R/M NPC was read out as “late breaking abstract (LBA)” for oral presentation at the ASCO Congress 2025. The Company is also currently conducting the Phase III clinical trial of combination therapy with MRG003 and pucotenlimab on R/M NPC. The encouraging data in phase II clinical trial of combination therapy on R/M NPC will be presented at the ESMO Congress 2025.HNSCC: As of June 30, 2025, the Company is conducting a randomized, open-label, multicenter Phase III clinical study on HNSCC. In terms of combination therapy with MRG003 and pucotenlimab, we are currently conducting the Phase II clinical trial on HNSCC, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The  European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and the Company will initiate the clinical trial in the second half of 2025.MRG004A (TF-ADC): The Company has completed the Phase I clinical study on solid tumors in China and the encouraging Phase Ib expansion data on PC will be presented at the ESMO Congress 2025. Protocol communication with CDE for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, MRG004A was granted BTD by the CDE in August 2025, which offers a brand-new treatment option to patients with pancreatic cancer.MRG006A (GPC3-ADC): MRG006A is a GPC3-targeted ADC with FIC potential globally. We received IND clearance from the FDA in January 2025. We are currently advancing Phase I clinical trial in China. In pre-clinical studies, MRG006A resulted in a robust and dose-dependent tumor growth inhibition on multiple CDX models and HCC PDX models. In the meantime, MRG006A also demonstrated good tolerability in the exploratory toxicology study.MRG007 (CDH17-ADC): We received the IND approval from the NMPA in June 2025 and are currently conducting a Phase Ia clinical trial for the treatment of unresectable locally advanced or metastatic solid tumors. MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025. In January 2025, the Company entered into an exclusive licensing agreement with ArriVent, pursuant to which the Company has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China. Under the terms of the agreement, the Company is eligible to receive up to US$1.2 billion in total in upfront payment and development, regulatory and sales milestones, together with tiered royalties on net sales. As of June 30, 2025, the upfront payment has been received.CG0070 (Oncolytic virus): CG0070 was granted BTD by the CDE in January 2025. CG0070 is currently in a MRCT Phase III clinical study conducted by the Company’s U.S. partner, CG Oncology. The latest encouraging data observed has been orally presented in the 120th American Urological Association Annual Meeting in April 2025. The Company has completed the Phase I clinical trial in China and are currently engaged in protocol communication with the CDE regarding the domestic bridging pivotal linical trial.Combination therapy layout: As of June 30, 2025, the Company has completed the Phase II trial of combination therapy with MRG002 and pucotenlimab in the treatment of HER2-expressing solid tumors, which has moved to first-line treatment, and protocol communication for phase III clinical trial has been completed. The Company has observed encouraging data on UC. In terms of combination therapy with MRG003 and pucotenlimab, the Company is currently conducting the Phase II clinical trial on HNSCC, which has moved to first-line treatment, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and we will initiate the clinical trial in the second half of 2025, which has been moved up to first-line treatment for advanced disease.Preclinical: Laying the groundwork for innovative platforms and innovative targetsThe Company continuously strives to build up and develop novel technology platforms as innovative engines for the Company. The Company has developed multiple innovative linker-payload platforms for ADC drug candidates, including the Hi-TOPi ADC platform and other early-stage platforms. During the reporting period, our innovative ADC platforms have achieved significant progress. Based on these innovation platforms, the Company has generated two ADC candidates, which are MRG006A with global first-in-class potential and MRG007 with global best-in-class potential, all of which have shown encouraging pre-clinical data and received IND approvals in China. Pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025.On August 1, 2025, the Company entered into a licensing transaction for the license-out and/or transfer of certain intellectual property rights relating to two preclinical assets developed by the Company’s proprietary T cell engager-TOPAbody platform with Excalipoint through entering into the Intellectual Property Assignment and License Agreement.The Company shall receive (i) an upfront payment in cash of US$10 million in aggregate, development and commercial milestone payments in cash of up to US$847.5 million in aggregate and sales royalties, holding a 10% interest, marking international recognition of the platform's value.Future Outlook: Accelerating the Commercialization of Core Products and Advancing Global Strategic DevelopmentIn respect of drug R&D, the Company will further focus on advancing strategic research and development priorities in next generation ADC drugs and IO bi/tri specific antibodies, while accelerating the commercialization of late-stage products. For our registrational stage product MRG003, the relevant authority is currently proceeding with the clinical and pharmaceutical evaluation in an orderly manner. The Company will concentrate our resources and endeavour to expedite the approval process. Meanwhile, our other key drug candidates are entering pivotal clinical stages. Protocol communication for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, we are currently conducting protocol communication with the CDE regarding the domestic pivotal clinical trial of CG0070. The Company will also explore further potential clinical value of our other innovative drug candidates, such as MRG006A and MRG007. Concurrently, the potential efficacy of combination therapies within our pipeline is being continuously explored, with greater clinical benefits striving to be delivered to a broader patient population.In terms of domestic commercialization, the Company will take further actions to enhance the market accessibility of PUYOUHENG (Pucotenlimab Injection), accelerating market penetration at all levels to further increase market share and enhance the Company's brand image and market recognition. At the same time, the Company will commence the preparation process for the commercial launch of MRG003 and continue to expand our marketing and commercialization teams.On the international front, the Company will ramp up our efforts to expand into the global market. We will expand our international network and explore new business development cooperation opportunities. The Company will remain committed to seeking more strategic partners worldwide to develop our ADC products and other innovative candidates through partnerships, licensing agreements, or joint ventures. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 22, 2025 - (ACN Newswire via SeaPRwire.com) - China International Development Corporation Limited (“the Company”; SEHK: 0264) is pleased to announce that it has entered into a definitive agreement to acquire a 20% equity interest in NVTHK Ltd. (“NVT”), a Hong Kong-based financial technology innovator and first mover in the Real-World Asset (“RWA”) tokenization market. This strategic acquisition positions the Company at the forefront of a sector expected to reshape global capital markets and deliver exponential growth in the years ahead.NVT — First Mover in a Transformative MarketNVT is the pioneering RWA tokenization infrastructure provider in Hong Kong, uniquely enabling primary issuance from top-tier financial institutions and on chain secondary trading of regulated tokenized assets through its robust OTC market place — the first full-scale ecosystem of its kind in the market.Its fully integrated, closed-loop ecosystem connects asset issuers, investors, and liquidity providers, unlocking unprecedented efficiency and liquidity for the financial industry.NVT’s prestigious institutional-grade clientele spans top financial institutions, asset managers, and Web3 innovators, including Cinda Asset Management, GF Securities, Golden Continent Asset Management, Animoca Brands, and HashKey Group. Its platform currently supports tokenized issuances across multiple financial product categories — including money market funds, structured products, bonds, private equity funds—demonstrating broad applicability and market acceptance.This Acquisition is Breakthrough for China International DevelopmentAccording to a BCG report dated April 2025, the global RWA tokenization market is forecast to grow from US$0.6 trillion in 2025 to US$18.9 trillion by 2033 in the midpoint scenario — a 53% compound annual growth rate. The sector’s rapid expansion reflects rising institutional and retail demand for high yield, transparent, and directly accessible asset classes.By acquiring a 20% stake in NVT, the Company gains:- A turnkey, proprietary institutional-grade tokenization platform — success-proven and fully regulated;- Access to the first RWA ecosystem in Hong Kong with secondary trading via an on chain OTC marketplace;- An established global distribution network with instant connectivity to liquidity providers, asset issuers, and investors globally;- Credibility and market access through alignment with a trusted RWA ecosystem serving blue chip clients.This acquisition accelerates the Company’s entry into the high growth RWA market at scale, without the delays, risks, and capital expenditure associated with building a platform from scratch. The Acquisition is also consistent with the Company’s commitments to exploring innovations and new business opportunities to diversify income streams.Strategic Collaboration AreasFollowing the investment, the Company and NVT will collaborate in two strategic areas:RWA Tokenization in Leather Production & Supply ChainLeveraging NVT’s platform, the Company will be a global first mover in tokenizing tangible and intangible assets within the leather industry—such as cash flows, receivables, inventory, and IP. This will unlock working capital, open new investment channels, automate settlements, and expand liquidity access worldwide.Expansion into New RWA VerticalsTogether, the Company and NVT will develop and scale RWA tokenization solutions for other industries, deploying the Company’s sector expertise and NVT’s proven infrastructure to capture untapped opportunities in multiple asset classes.Zhao Jingfei, CEO of China International Development Corporation Limited said:“This investment in NVT represents a breakthrough for our Company. NVT’s unmatched first mover position, its proven track record with prestigious institutional clients, and its unique on chain secondary trading capabilities place it in a category of its own. We are now positioned to participate meaningfully in a trillion dollar growth opportunity while modernizing our core business and delivering long term shareholder value.”Jay Zhao, the founder and CEO of NVT added:“Our mission is to leverage blockchain technology to redefine capital markets, with a particular focus on Hong Kong — the financial hub of Asia. By partnering with China Development, we are opening access to high quality assets from real-world industries and seamlessly integrating them into the capital market. This partnership not only enhances the strength of our platform but also creates significant opportunities for value creation across our ecosystem of partners, with a clear focus on maximizing long term shareholder returns. What we are building is just the beginning — the potential for new business models, innovative asset classes, and scalable growth ahead is truly limitless.”About NVTNVTHK Limited. (“NVT”) is a Hong Kong based fintech innovator specializing in real world asset (RWA) tokenization infrastructure, virtual asset brokerage systems, and stablecoin technology solutions. NVT is the first in Hong Kong to enable regulated tokenized assets to be traded on chain through its OTC marketplace, offering enterprise grade technology for issuers, investors, and intermediaries.About China International Development Corporation LimitedChina International Development Corporation Limited (“CIDC”) was incorporated in the Cayman Islands and is listed on the Main Board of The Stock Exchange of Hong Kong under stock code 0264. As an established investment holding company, CIDC has built a strong foundation in the manufacturing and distribution of high-quality leather products.  CIDC has proactively embarked on a strategy of innovation and transformation, seeking opportunities beyond its traditional core business. The Company is always committed to seeking opportunities for new business and value creation, as well as for timely expansion of the Company’s scope of operation and investments.For press enquiries:NVTHK LimitedOlivia Leung   Tel: 2522 3869 Email: Olivia.leung@newvisiongp.comWebsite: www.nvt.cim.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Ta Yang Group Holdings Limited (“Ta Yang Group” or the “Group”; Stock Code: 1991), a well-established Hong Kong-listed company with nearly two decades of market presence, plans to further advance comprehensively into the Web 4.0 field and artificial intelligence (AI) industry. The Group will leverage AI Digital Humans as its subsequent growth engine, integrating a Real World Assets (RWA) tokenization operation platform with its inherent global traffic marketing operation system to strategically deploy across three trillion-dollar sectors: education, gaming, and big health.Against the backdrop of AI fueling a new wave of global digitization, AI is evolving from a “technological tool” to the “core of transformation” for many enterprises, driving industries to change work methods, overcome efficiency boundaries, and reshape value paradigms. IDC research indicates that for every dollar invested in generative AI, enterprises can achieve a return on investment of 3.7 times; companies deeply embracing AI have realized an average value return cycle of 13 months. Over 50% of organizations are accelerating customized AI application development, converting short-term gains into long-term competitive advantages. PwC forecasts that by 2030, AI will be a global economic game-changer, contributing up to US$15.7 trillion in growth and adding approximately 26.1% to China’s GDP. It is no surprise that AI Digital Humans, as the core multi-modal interactive carriers across industries, are gradually transitioning from concept to industrial implementation.In 2023, the Group invested in Jusheng Technology Co., Ltd. (“Jusheng Technology”), a professional digital marketing services company. Jusheng Technology plans to launch its independently developed AI Digital Humans, integrating leading technologies such as machine learning, natural language processing (NLP), computer vision (CV), speech synthesis/recognition (TTS/STT), and compatible with the xAI Grok API. This AI Digital Human is at an industry-leading level and will be introduced to three major scenarios: education, gaming, and big health. This includes, but is not limited to: a “Virtual Teacher” AI Digital Human that can adjust speaking speed and learning difficulty in real time based on students’ attention; AI NPCs in games with personalized storylines that evolve based on different player choices; and a “Health Companion” AI Digital Human offering proactive suggestions based on individuals’ 24/7 health data such as heart rate and blood pressure. The Group plans a “phased iterative and gradual open” strategy, expecting to complete the core modules and underlying technology integration within six months, release AI Digital Human prototypes for the three scenarios in the following 6 to 18 months, and integrate these into Jusheng Technology’s marketing matrix. Between 18 and 36 months, the Group aims to open related APIs or SDKs and attract global developers to build an open ecosystem.Additionally, the Group intends to take advantage of this AI and digital transformation opportunity by using blockchain-based RWA to enable off-chain cash flow-generating asset projects to be captured in real time by AI Digital Humans and recorded in smart contracts. The Group will structure and issue layered packages of assets including educational copyrights and gaming IPs tailored to investors’ risk preferences. The target for this type of asset issuance is to pilot 10 high-quality projects in the first year, with plans to expand to 100 projects within three years, involving total asset values of HK$500 million. The Group aims to serve total asset values exceeding HK$5 billion within five years, establishing a multi-domain RWA asset operation platform.It is noteworthy that RWA transactions eliminate the need for traditional brokers or intermediaries, enabling a direct connection between the physical economy and virtual markets. According to Boston Consulting Group estimates, the RWA tokenization market could grow to a valuation of US$16 trillion by 2030, underscoring its vast market potential and promising outlook.Leveraging Jusheng Technology’s 20 years of cross-border marketing experience, Ta Yang will build a traffic system characterized by “comprehensive coverage + intelligent operation + scalable growth.” Jusheng Technology’s platforms cover overseas social media such as TikTok, Instagram, Facebook, as well as domestic channels like Douyin and WeChat Video Accounts, facilitating global user reach for customers. Utilizing AI technology, processes such as account nurturing, content generation, and targeted delivery will be fully automated to reduce operational costs and improve customer acquisition efficiency. Based on this, Ta Yang Group has a clear user growth target: to attract 1 million users in the first year to form an initial traffic pool, reach over 10 million users within three years, and build a native Web 4.0 traffic pool of hundreds of millions of users within five years, creating a “traffic – conversion – repurchase” cycle.Ms. Shi Qi, Chairlady of Ta Yang Group, stated, “Ta Yang is unveiling its AI transformation blueprint and formally entering the digital asset arena, marking a significant milestone for the Group and opening a new chapter for future development. We are grateful for investors’ recognition and confidence in our growth. As a well-established Hong Kong-listed company with nearly two decades of market history, this entry into the AI industry is expected to generate four types of revenue: income from AI Digital Human-driven traffic; revenue from providing AI+RWA one-stop financing consultancy services to SMEs; matchmaking fees related to RWA transactions, as well as digital advisory subscription fees; and multilingual, multicultural AI customer service and marketing outsourcing fees charged on a per-project or annual basis. Benefiting from its business model, Jusheng Technology has maintained positive cash flow in recent years, providing ample resources for this broader AI and digital transformation initiative. As the Group’s vision through Jusheng Technology in AI gradually materializes, we look forward to creating greater value and delivering promising returns for our shareholders.”About Ta Yang Group Holdings Limited (SEHK: 1991.HK)Ta Yang Group Holdings Limited (Stock Code: 1991) was established in 1991 and successfully listed on The Stock Exchange of Hong Kong Limited in 2007. It is a diversified enterprise combining three decades of industry experience with a forward-looking digital vision. Since its founding, the Group initially focused on the field of silicone input devices, specializing in the design and manufacture of core components used in consumer electronic devices, computers, laptops, mobile phones, and automotive peripherals. Leveraging a highly integrated production system, stringent quality control, and technological innovation capabilities, the Group has earned long-term trust from numerous globally renowned brand clients, laying a solid industrial foundation.With the deepening wave of global digital transformation, Ta Yang Group has keenly identified strategic opportunities in the digital economy era and decisively launched a comprehensive strategic transformation toward the Web 4.0 domain. Centered on “embracing technological change and reshaping the value ecosystem,” the Group precisely anchors on three core drivers: artificial intelligence (AI), Real World Assets (RWA) tokenization, and Hong Kong’s policy ecosystem. It is dedicated to bridging the transformation chain of “data — assets — value,” marking its leap from a traditional manufacturing enterprise to a digital economy pioneer.Currently, Ta Yang Group regards its Web 4.0 strategic transformation as a new starting point, focusing on the three trillion-dollar sectors of education, gaming, and big health. It aims to become a leading enterprise in the Asia-Pacific region across the dual arenas of AI and RWA, providing efficient value growth ecosystems for global investors, partners, and individual users. The Group is committed to continuously advancing high-quality development of the global digital economy and writing a new chapter from being an “industry deep cultivator” to a “digital ecosystem builder.” Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年8月21日 - (亞太商訊 via SeaPRwire.com) - 大洋集團控股有限公司 (「大洋集團」或「集團」；股份代號：1991) 作為在港上市近廿載的老牌港股，擬進一步向Web4.0領域及染指人工智能（AI）產業全面進軍，將以AI數字人作為其後續成長引擎，結合真實世界資産（Real World Assets，RWA）代幣化運營平台，及其固有的全球流量營銷運營體系，針對教育、遊戲、大健康三大萬億賽道進行戰略佈局。在人工智能（AI）為全球數字化捲起新浪潮的大局下，AI正從「技術工具」躍升成為不少企業的「變革核心」，並驅使各行業改變工作方式、突破效率邊界、重塑其價值邏輯。IDC研究顯示，企業每投資1元在生成式AI身上，其投資回報率可達3.7倍；而深度擁抱AI的企業已實現平均13個月的價值回報周期，超過50%的組織正加速定制化AI應用開發，將短期收益轉化爲長期競爭優勢。普華永道預測，到2030年，AI將成爲全球經濟的規則改變者，貢獻高達 15.7 萬億美元的增長，為中國經濟帶來約26.1%的 GDP增量。無怪AI數字人作為不同行業多模式交互核心載體，已逐步從概念邁向產業落地。大洋集團於2023年投資的專業數位營銷服務公司巨省科技有限公司（「巨省科技」）擬推出其自主研發、技術融合機器學習、自然語言處理（NLP）、計算機視覺（CV）、語音合成／識別（TTS／STT）等領先技術、可兼容xAI Grok API的AI數字人，此AI數字人處於行業領先水平，並擬面向教育、遊戲及大健康的三大場景推出，形成包括但不限於，如能夠根據學生專注力實時調整語速及學習難度的「虛擬老師」AI數字人、藉因應每位玩家不同選擇互動而衍生「玩家專屬」的劇情之AI NPC、可根據個人7x24小時的健康數據如心率、血壓等主動建議的「健康伴侶」AI數字人等；集團計劃採取「分階段疊代、逐步開放」的策略，即預期將於未來6個月內完成核心模塊及底層技術整合，並目標於緊接的第6至18個月就上述三大場景發佈AI數字人原型，並接入巨省科技之營銷矩陣，期望於第18至36個月內能開放相關API或SDK接口，並吸引全球開發者構建其開放式生態圈。除此之外，集團更擬透過是次向AI與數字化轉型的契機，計劃透過區塊鏈RWA（Real World Assets，真實世界資產），將具備現金流的鏈下資產項目通過AI數字人實時抓取寫進智能合約當中，並將針對教育版權、遊戲IP在內等資產進行分層打包及發行，以配合不同投資者的風險偏好，集團目標此類資產發行，首年將對10個優質項目進行「試水式」發行，冀能於未來3年擴展至100個項目，涉及資產規模總值5億港元；力爭5年內服務的資產規模總值能突破50億港元，打造出多領域RWA資產運營平台。值得留意的是，RWA交易過程中，無需傳統經紀商或中間機構的參與，便可實現實體經濟與虛擬市場的結合。根據波士頓諮詢顧問公司的估計 =，至2030年，RWA代幣化市場的市值規模可能成長至16萬億美元。由此可見，其巨大的市場潛力以至前景。依託巨省科技20年跨境投放經驗，大洋集團將構建「全域覆蓋+智能運營+規模增長」流量體系。巨省科技服務之平台覆蓋TikTok、Instagram、Facebook等海外社交平台及抖音、微信視頻號等國內渠道，有助客戶實現全球用戶觸達；並可借助AI技術實現賬號養號、內容生成、定向投放全流程自動化，降低運營成本，提升獲客效率。以此推算，大洋集團對用戶增長目標明確：首年引流100萬用戶構建初始流量池，目標3年內超千萬，5年內打造億級Web4.0原生流量池，形成「流量－轉化－複購」的循環。大洋集團將藉上述規劃打造「數據化（Digitalization）－資産化（Assetization）－代幣化（Tokenization）（下稱‧DAT）」閉環，實現價值三層轉化：於數據化階段，將教育教案、遊戲脚本等多元數據標準化，打破數據孤島；在資産化階段，將用戶交互沉澱換算為可量化資産，比如教育「個性化教研數據包」可提升AI數字人老師課程之續費率、遊戲「劇情擴展資産」延長遊戲生命周期等；在代幣化階段，將可通過滴灌通DRO模型質檢之達標資産上鏈發行，全球投資者可7×24小時交易，放大流動性溢價。針對上述AI及數字化轉型戰略藍圖的投入規劃，大洋集團預期首年投入1.3億港元，目標未來5年內實現現金流正向循環。大洋集團主席施琦女士表示：「大洋發佈助力企業AI與數字化轉型藍圖，並正式進入數字資產領域，標誌着集團一項重要里程碑，亦為未來更多元化發展掀開嶄新的一頁。我們感謝各投資者對公司以發展的肯定及信心。大洋集團作為一間在港上市近廿載的老牌港股，透過是次涉足AI產業的舉措，未來有望衍生四種收入，包括AI數字人引流的收入、為中小企業提供 AI+RWA 一站式融資諮詢的收入、與RWA交易相關的撮合手續費以至數字投顧訂閱費、以及按項目或年費提供多語言、多文化 AI 客服與營銷外包收入，且巨省科技受惠其業態，近年持續保持正向現金流，亦為是次其向AI及數字轉型進一步拓展大計，提供充裕的自有資源，而隨着集團透過巨省科技走入AI領域的藍圖逐步變成現實，屆時可望為股東創造更多價值並帶來理想回報。」關於大洋集團控股有限公司(股份代號: 1991)大洋集團控股有限公司（股票代號：1991）成立於 1991 年，2007 年在香港聯合交易所有限公司成功上市，是一家兼具三十年産業積澱與前瞻數字視野的多元化企業。自創立以來，集團早期聚焦矽膠輸入設備領域，專業設計及製造用於消費電子裝置、計算機、筆記本電腦、手提電話及汽車周邊産品的核心部件，憑藉高度整合的生産體系、嚴苛的品質管控與技術創新能力，贏得全球眾多知名品牌客戶的長期信賴，奠定了堅實的産業根基。隨着全球數字化轉型浪潮的深化，大洋集團敏銳洞察數字經濟時代的戰略機遇，果斷啓動向 Web4.0 領域的全方位戰略轉型，以「擁抱技術變革、重構價值生態」為核心方向，精準錨定人工智能（AI）、真實世界資産（RWA）代幣化及香港政策生態三大核心驅動力，致力於打通 「數據 — 資産 — 價值」 的轉化鏈路，開啓從傳統製造向數字經濟領航者的跨越。當前，大洋集團正以 Web4.0 戰略轉型為新起點，聚焦教育、游戲、大健康三大萬億賽道，致力於成為亞太地區 AI 與 RWA 雙賽道的領先企業，為全球投資者、合作夥伴及個人用戶提供高效的價值增長生態，持續推動全球數字經濟高質量發展，寫下從「産業深耕者」到「數字生態構建者」的全新一頁。 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025年中期業績亮點- 業務總收益同比增長9.40%至約新台幣585.31百萬元- 毛利同比增長28.98%至約新台幣201.97百萬元- 整體毛利率則上升5.24個百分點至約34.51%- 本公司擁有人應佔期間全面收益總額同比大幅增長118.02%約至新台幣68.24百萬元- 統包解決方案的收益約新台幣113.69百萬元- 每股基本盈利同比增長25.84%至約為新台幣4.87仙香港，2025年8月21日 - (亞太商訊 via SeaPRwire.com) - 靖洋集團控股有限公司（「  靖洋集團」或「集團」，股份代號：8257.HK）宣佈截至 2025年6月 30 日止六個月（「期內」）之中期業績。期內，集團業績呈現穩健增長態勢。集團總收益達約新台幣585.31百萬元，同比增長9.40%。毛利同比增長28.98%，達約新台幣201.97百萬元，而整體毛利率則上升5.24個百分點至約34.51%。本公司擁有人應佔期間全面收益總額約新台幣68.24百萬元，同比大幅增長118.02%。每股基本盈利約為新台幣4.87 仙，同比增長25.84%。期內，統包解決方案的收益約新台幣113.69百萬元，佔集團總收益約19.42%。零件及二手半導體製造設備買賣的收益約新台幣471.62百萬元，零件及買賣二手半導體製造設備佔集團總收益約80.58%。本集團秉持著審慎、穩健的核心策略，致力強化與現有國際客戶合作的穩定性和持續性，同時積極拓展新客戶以分散風險。期內，本集團源自美國業務的收入較去年大幅增加78.54%，佔集團總收益約38.68%，而源自台灣業務的收入則較去年增加48.97%，佔集團總收益約49.69%。2025 年上半年，全球半導體市場延續增長態勢。在AI 等新技術的驅動下，汽車電子、新能源、物聯網、大數據和人工智能等領域的新技術、新產品滲透率持續提升。此外，「人工智能+」、「5G+」等前沿技術的深化發展，以及AI 算力需求的快速增長，均成為推動半導體需求的重要動力，為半導體企業營造了良好的發展環境。根據半導體產業協會最新報告，2025年5月全球半導體銷售額達590億美元，較2024年5月的492億美元增長19.8%，連續19個月實現同比增長；環比則增長3.5%。全球晶片市場的增長主要受美洲和亞太地區強勁需求推動。靖洋集團主席兼行政總裁楊名翔先生總結：「在AI 技術的強勁驅動下，半導體行業迎來經濟利潤快速增長期。然而，當前國際形勢波動，其亦面臨供應鏈穩定性的挑戰。本集團將審時度勢，穩中求進，持續提升核心價值與競爭力，為股東創造可持續的長期投資回報。」                                                                            關於靖洋集團控股有限公司（股份代號：8257.HK）靖洋集團控股有限公司為一間總部位於台灣的零件及二手半導體製造設備的統包解決方案供應商及出口商。集團自於2009年開始業務以來，主要為客戶提供零件二手半導體製造設備件的統包解決方案，按客戶需要改造及/或升級其生產系統的半導體設備，亦從事半導體製造設備及其零件買賣。集團所提供的半導體製造設備及零件包括熱爐管、顯影裝置等，用於半導體的前端製造過程、晶圓加工，如沉積、光阻塗佈及顯影，更可廣泛應用於手機、遊戲機、DVD播放機，以及車用感應器等數碼電子產品。本新聞稿由滙滔顧問有限公司代表靖洋集團控股有限公司發佈。詳情垂詢：劉育然小姐電話：(852) 2529 7999電郵：Natural.lau@vitalink.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月21日 - (亞太商訊 via SeaPRwire.com) - 聚焦於腫瘤治療領域的創新型生物製藥公司--樂普生物科技股份有限公司(「樂普生物」或「公司」，股份代號：2157.HK)公佈2025年中期業績。報告期內，公司業務呈現強勁增長態勢，首次實現盈利，核心產品銷售與國際授權業務齊頭並進，ADC管線多產品進入關鍵臨床階段，全球商業化佈局加速推進。作為一家立足中國、面向全球的聚焦於腫瘤治療領域（尤其是靶向治療及免疫治療）的創新型生物製藥企業。樂普生物致力於通過全面且先進的ADC技術開發平台開發創新型ADC，並旨在開發出優化、創新的藥物，更好地填補癌症患者的臨床需求缺口。公司致力於通過充分整合自主創新能力及戰略合作，持續開發市場差異化產品管線。隨着ADC候選藥物即將進入商業化階段，公司已建立並正在逐步擴大內部生產能力以滿足業務發展的需求。目前，樂普生物已戰略性佈局了多個腫瘤產品管線。就臨床階段候選藥物而言，公司的產品中有一種臨床/商業化階段候選藥物、九種臨床階段候選藥物（包括一種透過合營企業共同開發的藥物）、三種臨床階段的候選藥物的聯合療法。其中一種候選藥物已獲得兩種靶向適應症的上市批准，其他適應症臨床試驗正在進行中。在九種臨床階段候選藥物中，七種靶向療法藥物，兩種免疫治療藥物（屬於一種溶瘤病毒藥物及T細胞激動性抗體）。截至報告期末，通過商業化及業務開發活動，樂普生物在研發能力變現方面取得重要里程碑：普佑恆(R)（普特利單抗注射液）已完成商業化全流程，目前正處於銷售快速增長階段，另有4款產品CMG901、MRG007以及两项临床前TCE资产也通過業務開發活動成功達成授權合作。CMG901的全球權益已授權給AstraZeneca，MRG007的大中華區以外權益已授權給ArriVent，两项临床前TCE资产与Excalipoint达成合作。收入規模實現3.5倍跨越式增長 財務指標全面改善2025年上半年，公司在推進產品管線及業務營運方面均取得重大進展，錄得總收入約人民幣4.66億元，較2024年同期的人民幣1.33億元增長350%。就許可業務而言錄得收入約人民幣3.09億元，主要來自MRG007的對外授權許可；錄得銷售普佑恆(R)（普特利單抗注射液）的收入約人民幣1.51億元，較2024年同期大幅增加58.8%。此外，就提供CDMO服務錄得收入約人民幣630萬元。於報告期內，公司首次實現盈利，期內利潤約人民幣2930萬元，較2024年同期實現扭虧為盈；經營活動產生的現金淨額約人民幣4670萬元，現金及現金等價物增至約人民幣4.73億元，較2024年同期實現經營現金流量淨額轉正；研發開支約人民幣2.02億元，較2024年同期下降6.6%，在保障核心管線推進的同時，成本控制成效顯現。公司積極發展與各種業務渠道合作夥伴的合作關係。截至2025年6月30日，公司已在中國28個省份的採購平台上完成了招標程序，已通過各種銷售渠道覆蓋中國約118個城市，將進一步擴大銷售網絡。ADC管線多產品進入關鍵階段 聯合療法潛力凸顯 國際授權成果豐碩於2025年上半年，公司繼續專注於其候選藥物的研發，同時不斷評估與腫瘤治療範圍及候選藥物涵蓋的廣泛適應症相關的市場需求和競爭格局，以最大化提高其產品管線的競爭力。其中，MRG003用於治療NPC適應症即將獲批，其他核心候選藥物進入關鍵註冊性臨床階段。MRG003（EGFR-ADC）：NPC：MRG003關於治療R/M NPC適應症正在接受NDA審評，且亦已獲國家藥監局CDE授予的優先審評。監管機構目前正進行MRG003的臨床及藥學審核。用於治療R/M NPC的IIb期關鍵臨床研究的良好數據於2025年ASCO大會上作為「重磅研究摘要」(LBA)讀出，且以口頭匯報形式呈現。目前公司亦正在進行MRG003與普特利單抗聯合治療R/M NPC的III期臨床試驗。該聯合療法的II期臨床試驗的良好數據將於2025年ESMO大會上呈現。HNSCC：截至2025年6月30日，公司正在進行HNSCC的隨機、開放、多中心III期臨床研究。對於MRG003與普特利單抗的聯合治療，目前正在進行HNSCC的II期臨床試驗，且II期臨床試驗的良好數據將於2025年ESMO大會上呈現。2025年6月，該聯合療法用於治療LA-SCCHN的II期臨床試驗的臨床試驗申請(CTA)獲歐洲藥品管理局(EMA)批准，公司將於2025年下半年開展該臨床試驗。MRG004A（TF-ADC）：公司已在中國完成實體瘤I期臨床研究，且PC適應症的Ib期良好數據將於2025年ESMO大會上呈現。就MRG004A的關鍵註冊性臨床試驗方案與CDE的溝通已完成，並已於2025年8月進入III期臨床試驗階段。此外，MRG004A於2025年8月獲CDE授予BTD，為胰腺癌患者提供全新的治療選擇。MRG006A（GPC3-ADC）：MRG006A是一款具有全球FIC潛力的GPC3靶向ADC產品，於2025年1月獲得FDA的IND批准，目前正在中國推進I期臨床試驗。於臨床前研究中，MRG006A在多種CDX模型及HCC PDX模型中展現出強大的劑量依賴性的對腫瘤的生長抑制作用。同時，MRG006A亦在探索性毒理學研究中表現出良好的耐受性。MRG007（CDH17-ADC）：2025年6月獲國家藥監局IND批准，目前正在開展治療不可切除的局部晚期或轉移性實體瘤的Ia期臨床試驗。其在消化道癌的臨床前模型中表現出強大的抗腫瘤活性，並在IND支持性研究中顯示出良好的治療指數。MRG007的臨床前數據已於2025年4月的AACR年會上呈報。2025年1月，公司與ArriVent訂立獨家許可協議，授予ArriVent在大中華區以外地區開發、製造和商業化MRG007的全球獨家許可。根據協議條款，公司有資格獲得總計最高達12億美元的首付款及開發、註冊及銷售里程碑付款，連同銷售淨額的分級特許權使用費。截至2025年6月30日，已收到該筆首付款。CG0070（溶瘤病毒）：CG0070於2025年1月獲CDE授予BTD。目前公司的美國合作夥伴CG Oncology正在針對CG0070進行MRCT III期臨床研究。觀察到的最新良好數據已在2025年4月第120屆美國泌尿外科協會年會上以口頭匯報形式呈現。公司已完成在中國的I期臨床試驗，目前正與CDE就國內關鍵橋接臨床試驗進行方案溝通。聯合療法布局：截至2025年6月30日，公司已完成MRG002與普特利單抗聯合治療HER2表達實體瘤的II期試驗（該試驗已提線至一線治療），且III期臨床試驗的方案溝通已完成。公司已於治療UC中觀察到良好的數據；在MRG003與普特利單抗聯合治療方面，公司目前正在進行HNSCC的II期臨床試驗（該試驗已提線至一線治療），而良好的II期臨床試驗數據將於2025年ESMO大會上公佈。2025年6月，該聯合療法用於治療LA-SCCHN的II期臨床試驗的臨床試驗申請(CTA)獲歐洲藥品管理局(EMA)批准，將於2025年下半年啟動臨床試驗（該試驗已提線至一線治療之前局晚期）。臨床前：佈局創新平台和創新靶點公司持續致力於建立和開發新型技術平台，將其作為本公司的創新引擎。公司亦已為ADC候選藥物開發多個創新的鏈接體－有效載荷平台，包括Hi-TOPi ADC平台及其他早期階段的平台。於報告期內，公司的創新ADC平台取得了重大進展。依託該等創新平台，公司已開發出兩款ADC候選藥物，分別為具有全球首創新藥潛力的MRG006A及具有全球同類最優潛力的MRG007，均已顯示良好的臨床前數據，並於中國獲得了IND批准。MRG007的臨床前數據已於2025年4月在AACR年會上呈現。於2025年8月1日，本公司已與Excalipoint訂立知識產權轉讓及許可協議，就對外授權及/或轉讓與公司專有的T細胞銜接器平台TOPAbody開發的兩項臨床前資產有關的若干知識產權訂立許可交易。公司將收取總額為1000萬美元的現金首付款、總額最高為8.475億美元的研發及商業里程碑付款及銷售特許權使用費，並持有其10%股權，標誌着平台價值獲得國際認可。未來展望：加速核心產品商業化 推進全球戰略布局在藥物研發方面，公司將進一步聚焦於推動下一代ADC藥物及免疫腫瘤雙╱三特異性抗體的戰略研發，同時加快後期產品的商業化。對於註冊階段產品MRG003，有關監管機構目前正有序進行臨床及藥學審核，公司將集中資源，全力加速其獲批進程。同時，其他核心候選藥物進入臨床關鍵階段。MRG004A關鍵性臨床試驗方案溝通已完成，且已於2025年8月進入III期臨床試驗階段。此外，目前正與CDE就CG0070的國內關鍵臨床試驗進行方案溝通。公司亦將探索MRG006A及MRG007等其他創新候選藥物的更多潛在臨床價值。同時，公司正在不斷探索管線內聯合療法的潛在療效，努力為更廣泛的患者群體帶來更大的臨床效益。在國內商業化方面，公司將採取進一步措施提高普佑恆(R)（普特利單抗注射液）的市場可及性，加快各級市場滲透，進一步擴大市場份額；提升公司的品牌形象及市場認知度。同時，公司將開始籌備MRG003的商業化上市，並繼續擴大營銷及商業化團隊。在國際方面，公司將加大在全球市場的拓展力度，擴大國際網絡，並探索新的業務開發合作機會。公司將繼續致力於在全球範圍內尋找更多戰略合作夥伴，通過合作、授權協議或合資企業等方式開發公司的ADC產品和其他創新候選藥物。 Copyright 2025 亞太商訊 via SeaPRwire.com.